Abstract:Background: Early goal-directed therapy (EGDT) is recommended in international guidance for the resuscitation of patients presenting with early septic shock. However, adoption has been limited and uncertainty remains over its clinical effectiveness and cost-effectiveness. Objectives: The primary objective was to estimate the effect of EGDT compared with usual resuscitation on mortality at 90 days following randomisation and on incremental cost-effectiveness at 1 year. The secondary objectives were to compare EGDT with usual resuscitation for requirement for, and duration of, critical care unit organ support; length of stay in the emergency department (ED), critical care unit and acute hospital; health-related quality of life, resource use and costs at 90 days and at 1 year; all-cause mortality at 28 days, at acute hospital discharge and at 1 year; and estimated lifetime incremental cost-effectiveness. Design: A pragmatic, open, multicentre, parallel-group randomised controlled trial with an integrated economic evaluation. Setting: Fifty-six NHS hospitals in England. Participants: A total of 1260 patients who presented at EDs with septic shock. Interventions: EGDT (n = 630) or usual resuscitation (n = 630). Patients were randomly allocated 1 : 1. Main outcome measures: All-cause mortality at 90 days after randomisation and incremental net benefit (at £20,000 per quality-adjusted life-year) at 1 year. Results: Following withdrawals, data on 1243 (EGDT, n = 623; usual resuscitation, n = 620) patients were included in the analysis. By 90 days, 184 (29.5%) in the EGDT and 181 (29.2%) patients in the usual-resuscitation group had died [p = 0.90; absolute risk reduction -0.3%, 95% confidence interval (CI) -5.4 to 4.7; relative risk 1.01, 95% CI 0.85 to 1.20]. Treatment intensity was greater for the EGDT group, indicated by the increased use of intravenous fluids, vasoactive drugs and red blood cell transfusions. Increased treatment intensity was reflected by significantly higher Sequential Organ Failure Assessment scores and more advanced cardiovascular support days in critical care for the EGDT group. At 1 year, the incremental net benefit for EGDT versus usual resuscitation was negative at -£725 (95% CI -£3000 to £1550). The probability that EGDT was more cost-effective than usual resuscitation was below 30%. There were no significant differences in any other secondary outcomes, including health-related quality of life, or adverse events. Limitations: Recruitment was lower at weekends and out of hours. The intervention could not be blinded. Conclusions: There was no significant difference in all-cause mortality at 90 days for EGDT compared with usual resuscitation among adults identified with early septic shock presenting to EDs in England. On average, costs were higher in the EGDT group than in the usual-resuscitation group while quality-adjusted life-years were similar in both groups; the probability that it is cost-effective is < 30%. Future work: The ProMISe (Protocolised Management In Sepsis) trial completes the planned trio of evaluations of EGDT across the USA, Australasia and England; all have indicated that EGDT is not superior to usual resuscitation. Recognising that each of the three individual, large trials has limited power for evaluating potentially important subgroups, the harmonised approach adopted provides the opportunity to conduct an individual patient data meta-analysis, enhancing both knowledge and generalisability. Trial registration: Current Controlled Trials ISRCTN36307479. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 97. See the NIHR Journals Library website for further project information.

A Multicentre Study on Early Goal-Directed Therapy of Severe Sepsis and Septic Shock Patients in the ICU: Collaborative Study Group on Early Goal-Directed Therapy in Zhejiang Province, China

Early Goal-Directed Resuscitation for Patients with Severe Sepsis and Septic Shock: a Meta-Analysis and Trial Sequential Analysis

Early Management of Sepsis with Emphasis on Early Goal Directed Therapy: AME Evidence Series 002

[Clinical Evaluation of Execution of Early Goal Directed Therapy in Septic Shock].

Assessment of gastric intramucosal pH in early goal-directed therapy for elderly patients with septic shock

Effects of Goal Directed Therapy for Adult Patients in Sepsis: A Systemic Review and Meta-Analysis of Randomized Controlled Trials

Early outcome of early-goal directed therapy for patients with sepsis or septic shock: a systematic review and meta-analysis of randomized controlled trials

Early Goal-Directed Therapy:Status and Renew

Early Goal-Directed and Lactate-Guided Therapy in Adult Patients with Severe Sepsis and Septic Shock: a Meta-Analysis of Randomized Controlled Trials

Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock

Success of applying early goal-directed therapy for septic shock patients in the emergency department

Early goal-directed therapy vs usual care in the treatment of severe sepsis and septic shock: a systematic review and meta-analysis

Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis

Effect of EGDT on Tissue Perfusion in Patients with Septic Shock

Effects of early goal directed therapy on microcirculation in patients with sepsis shock

Assessment of Central Venous-to-arterial CO2 Difference During Early Goal-Directed Therapy in Patients with Septic Shock

Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A Secondary Analysis of Two Multicenter International Trials

Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock

Trial of early, goal-directed resuscitation for septic shock

Prolonged Length of Stay in the Emergency Department and Increased Risk of Hospital Mortality in Patients with Sepsis Requiring ICU Admission

Effectiveness of Anisodamine for the Treatment of Critically Ill Patients with Septic Shock (acidosis Study): Study Protocol for Randomized Controlled Trial